Home » Stocks » AERI

Aerie Pharmaceuticals, Inc. (AERI)

Stock Price: $18.39 USD 2.58 (16.32%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $18.01 -0.38 (-2.07%) Feb 26, 5:51 PM
Market Cap 860.92M
Revenue (ttm) 83.14M
Net Income (ttm) -183.10M
Shares Out 45.90M
EPS (ttm) -3.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $18.39
Previous Close $15.81
Change ($) 2.58
Change (%) 16.32%
Day's Open 16.23
Day's Range 15.76 - 18.87
Day's Volume 1,646,451
52-Week Range 9.01 - 19.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 days ago

Aerie (AERI) delivered earnings and revenue surprises of -5.33% and 13.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 days ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class the...

Business Wire - 5 days ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...

Business Wire - 1 week ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...

Business Wire - 1 month ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...

Zacks Investment Research - 2 months ago

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 3 months ago

Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.

Business Wire - 3 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...

Business Wire - 3 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...

Seeking Alpha - 3 months ago

Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Aerie (AERI) reports a narrower-than-expected loss and revenues beat estimates in the third quarter of 2020.

Seeking Alpha - 3 months ago

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido On Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 3 months ago

Aerie (AERI) delivered earnings and revenue surprises of 19.75% and 4.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class the...

Zacks Investment Research - 3 months ago

Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...

Business Wire - 4 months ago

OSAKA, Japan & DURHAM, N.C.--(BUSINESS WIRE)--Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered in...

Business Wire - 4 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class the...

Zacks Investment Research - 4 months ago

The FDA accepts Aerie's (AERI) investigational new drug application for AR-15512 eye drop for dry eye disease.

Business Wire - 4 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class th...

Business Wire - 5 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class the...

Business Wire - 5 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

Business Wire - 5 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

Zacks Investment Research - 5 months ago

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 6 months ago

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.

Business Wire - 6 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

Business Wire - 6 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

Zacks Investment Research - 6 months ago

Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 7 months ago

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

The Motley Fool - 7 months ago

Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?

Seeking Alpha - 8 months ago

Aerie has 2 marketed products and decent pipeline after a recent acquisition.

Zacks Investment Research - 8 months ago

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 9 months ago

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Aerie (AERI) delivered earnings and revenue surprises of -12.00% and -3.32%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.

The Motley Fool - 10 months ago

Success in clinical trials doesn't guarantee success on the market.

Other stocks mentioned: AXSM, BIIB, BLUE, PBYI, PFE, RIGL
Zacks Investment Research - 11 months ago

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 1 year ago

The eye-care company reported better-than-expected fourth-quarter 2019 product revenue.

Zacks Investment Research - 1 year ago

Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.

Seeking Alpha - 1 year ago

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Aerie (AERI) delivered earnings and revenue surprises of -28.00% and 24.17%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.

Zacks Investment Research - 1 year ago

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

InvestorPlace - 1 year ago

For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.

Other stocks mentioned: AKBA, CYTK, NVAX, TBIO
Zacks Investment Research - 1 year ago

Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.

The Motley Fool - 1 year ago

Disappointing early sales results for its newest treatments, Rhopressa and Rocklatan, haven't shaken the company's confidence. Wall Street is a different story.

The Motley Fool - 1 year ago

Slow sales of its glaucoma drugs is forcing management to cut its sales guidance.

Zacks Investment Research - 1 year ago

Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.

About AERI

Aerie Pharmaceuticals, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The com... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Oct 25, 2013
CEO
Vicente Anido
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
AERI
Full Company Profile

Financial Performance

In 2020, AERI's revenue was $83.14 million, an increase of 18.96% compared to the previous year's $69.89 million. Losses were -$183.10 million, -8.26% less than in 2019.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for AERI stock is "Buy." The 12-month stock price forecast is 26.83, which is an increase of 45.89% from the latest price.

Price Target
$26.83
(45.89% upside)
Analyst Consensus: Buy